144 related articles for article (PubMed ID: 22850484)
1. LRRK2 expression is enriched in the striosomal compartment of mouse striatum.
Mandemakers W; Snellinx A; O'Neill MJ; de Strooper B
Neurobiol Dis; 2012 Dec; 48(3):582-93. PubMed ID: 22850484
[TBL] [Abstract][Full Text] [Related]
2. Differential LRRK2 expression in the cortex, striatum, and substantia nigra in transgenic and nontransgenic rodents.
West AB; Cowell RM; Daher JP; Moehle MS; Hinkle KM; Melrose HL; Standaert DG; Volpicelli-Daley LA
J Comp Neurol; 2014 Aug; 522(11):2465-80. PubMed ID: 24633735
[TBL] [Abstract][Full Text] [Related]
3. (G2019S) LRRK2 causes early-phase dysfunction of SNpc dopaminergic neurons and impairment of corticostriatal long-term depression in the PD transgenic mouse.
Chou JS; Chen CY; Chen YL; Weng YH; Yeh TH; Lu CS; Chang YM; Wang HL
Neurobiol Dis; 2014 Aug; 68():190-9. PubMed ID: 24830390
[TBL] [Abstract][Full Text] [Related]
4. The cannabinoid-1 receptor is abundantly expressed in striatal striosomes and striosome-dendron bouquets of the substantia nigra.
Davis MI; Crittenden JR; Feng AY; Kupferschmidt DA; Naydenov A; Stella N; Graybiel AM; Lovinger DM
PLoS One; 2018; 13(2):e0191436. PubMed ID: 29466446
[TBL] [Abstract][Full Text] [Related]
5. Expression and localization of Parkinson's disease-associated leucine-rich repeat kinase 2 in the mouse brain.
Higashi S; Moore DJ; Colebrooke RE; Biskup S; Dawson VL; Arai H; Dawson TM; Emson PC
J Neurochem; 2007 Jan; 100(2):368-81. PubMed ID: 17101029
[TBL] [Abstract][Full Text] [Related]
6. Lack of exacerbation of neurodegeneration in a double transgenic mouse model of mutant LRRK2 and tau.
Mikhail F; Calingasan N; Parolari L; Subramanian A; Yang L; Flint Beal M
Hum Mol Genet; 2015 Jun; 24(12):3545-56. PubMed ID: 25804954
[TBL] [Abstract][Full Text] [Related]
7. Expression of the LRRK2 gene in the midbrain dopaminergic neurons of the substantia nigra.
Han BS; Iacovitti L; Katano T; Hattori N; Seol W; Kim KS
Neurosci Lett; 2008 Sep; 442(3):190-4. PubMed ID: 18634852
[TBL] [Abstract][Full Text] [Related]
8. Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.
Tsika E; Nguyen AP; Dusonchet J; Colin P; Schneider BL; Moore DJ
Neurobiol Dis; 2015 May; 77():49-61. PubMed ID: 25731749
[TBL] [Abstract][Full Text] [Related]
9. A comparative analysis of leucine-rich repeat kinase 2 (Lrrk2) expression in mouse brain and Lewy body disease.
Melrose HL; Kent CB; Taylor JP; Dachsel JC; Hinkle KM; Lincoln SJ; Mok SS; Culvenor JG; Masters CL; Tyndall GM; Bass DI; Ahmed Z; Andorfer CA; Ross OA; Wszolek ZK; Delldonne A; Dickson DW; Farrer MJ
Neuroscience; 2007 Jul; 147(4):1047-58. PubMed ID: 17611037
[TBL] [Abstract][Full Text] [Related]
10. Localization of Parkinson's disease-associated LRRK2 in normal and pathological human brain.
Higashi S; Biskup S; West AB; Trinkaus D; Dawson VL; Faull RL; Waldvogel HJ; Arai H; Dawson TM; Moore DJ; Emson PC
Brain Res; 2007 Jun; 1155():208-19. PubMed ID: 17512502
[TBL] [Abstract][Full Text] [Related]
11. Anatomical localization of leucine-rich repeat kinase 2 in mouse brain.
Melrose H; Lincoln S; Tyndall G; Dickson D; Farrer M
Neuroscience; 2006; 139(3):791-4. PubMed ID: 16504409
[TBL] [Abstract][Full Text] [Related]
12. Parkinson's disease-linked leucine-rich repeat kinase 2(R1441G) mutation increases proinflammatory cytokine release from activated primary microglial cells and resultant neurotoxicity.
Gillardon F; Schmid R; Draheim H
Neuroscience; 2012 Apr; 208():41-8. PubMed ID: 22342962
[TBL] [Abstract][Full Text] [Related]
13. Lrrk2 and alpha-synuclein are co-regulated in rodent striatum.
Westerlund M; Ran C; Borgkvist A; Sterky FH; Lindqvist E; Lundströmer K; Pernold K; Brené S; Kallunki P; Fisone G; Olson L; Galter D
Mol Cell Neurosci; 2008 Dec; 39(4):586-91. PubMed ID: 18790059
[TBL] [Abstract][Full Text] [Related]
14. Distribution of PINK1 and LRRK2 in rat and mouse brain.
Taymans JM; Van den Haute C; Baekelandt V
J Neurochem; 2006 Aug; 98(3):951-61. PubMed ID: 16771836
[TBL] [Abstract][Full Text] [Related]
15. Nigrostriatal pathology with reduced astrocytes in LRRK2 S910/S935 phosphorylation deficient knockin mice.
Zhao Y; Keshiya S; Atashrazm F; Gao J; Ittner LM; Alessi DR; Halliday GM; Fu Y; Dzamko N
Neurobiol Dis; 2018 Dec; 120():76-87. PubMed ID: 30194047
[TBL] [Abstract][Full Text] [Related]
16. Developmental regulation of leucine-rich repeat kinase 1 and 2 expression in the brain and other rodent and human organs: Implications for Parkinson's disease.
Westerlund M; Belin AC; Anvret A; Bickford P; Olson L; Galter D
Neuroscience; 2008 Mar; 152(2):429-36. PubMed ID: 18272292
[TBL] [Abstract][Full Text] [Related]
17. Changes in matrix metalloprotease activity and progranulin levels may contribute to the pathophysiological function of mutant leucine-rich repeat kinase 2.
Caesar M; Felk S; Zach S; Brønstad G; Aasly JO; Gasser T; Gillardon F
Glia; 2014 Jul; 62(7):1075-92. PubMed ID: 24652679
[TBL] [Abstract][Full Text] [Related]
18. Enhanced dendritogenesis and axogenesis in hippocampal neuroblasts of LRRK2 knockout mice.
Paus M; Kohl Z; Ben Abdallah NM; Galter D; Gillardon F; Winkler J
Brain Res; 2013 Feb; 1497():85-100. PubMed ID: 23270607
[TBL] [Abstract][Full Text] [Related]
19. Expression analysis of Lrrk1, Lrrk2 and Lrrk2 splice variants in mice.
Giesert F; Hofmann A; Bürger A; Zerle J; Kloos K; Hafen U; Ernst L; Zhang J; Vogt-Weisenhorn DM; Wurst W
PLoS One; 2013; 8(5):e63778. PubMed ID: 23675505
[TBL] [Abstract][Full Text] [Related]
20. LRRK2 expression in idiopathic and G2019S positive Parkinson's disease subjects: a morphological and quantitative study.
Sharma S; Bandopadhyay R; Lashley T; Renton AE; Kingsbury AE; Kumaran R; Kallis C; Vilariño-Güell C; O'Sullivan SS; Lees AJ; Revesz T; Wood NW; Holton JL
Neuropathol Appl Neurobiol; 2011 Dec; 37(7):777-90. PubMed ID: 21696411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
